TG治疗小组报告说,2024年MS药物Briumvi的收入为310M美元,预计2025年将达到540M美元。 TG Therapeutics reports $310M in 2024 revenue for MS drug Briumvi, forecasts $540M for 2025.

TG Therapeutics 报告了其多发性硬化症治疗药物 Briumvi 的 2024 年第四季度和全年初步业绩，预计第四季度美国净产品收入为 1.036 亿美元，全年为 3.1 亿美元。 TG Therapeutics reported preliminary Q4 and full-year 2024 results for its multiple sclerosis treatment, Briumvi, with expected U.S. net product revenue of $103.6 million for Q4 and $310 million for the year. 2025年,该公司预计全球收入总额为5.4亿美元,包括来自布里乌姆维的5.25亿美元。 For 2025, the company targets total global revenue of $540 million, including $525 million from Briumvi. TG治疗公司的股票在市场前贸易中上涨了5.38%,达到29.16美元。 TG Therapeutics' stock rose 5.38% to $29.16 in pre-market trading.